Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes

 Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes

Lilly Reports Results of Tirzepatide in SURPASS-4 Study for Patients with Type 2 Diabetes

Shots:

  • SURPASS-4 study involves assessing tirzepatide (5/10/15mg) vs insulin glargine in 2002 adults in a ratio (1:1:1:3) with T2D inadequately controlled with at least 1 and up to 3 oral antihyperglycemic medications who have increased CV risk
  • The study met its 1EPs and 2EPs led to superior A1C and body weight reductions for both estimands. @52wks. A1C reduction (-2.24% / -2.43%/ -2.58% vs -1.44%); Weight reduction (-7.1/ -9.5/ -11.7kg vs +1.9 kg); patients achieving A1C <7% (81.0%/ 88.2%/ 90.7% vs 50.7%); patients achieving A1C <5.7% (23.0%/ 32.7%/ 43.1% vs 3.4%) respectively
  • Lilly plan to submit registration package to regulatory authorities by the end of 2021

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Fox Business

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post